Open-Angle Glaucoma: How Rising Eye Pressure Silently Steals Sight

The normal plumbing: how the eye sets its own pressure

The front of the eye is continuously bathed by aqueous humor, a clear fluid that nourishes the avascular cornea and lens and maintains the eye's shape and pressure. The ciliary body secretes roughly 2–3 µL/min of aqueous into the posterior chamber. The fluid flows forward through the pupil into the anterior chamber, then drains out mainly through the trabecular meshwork — a sieve-like tissue in the angle where the iris meets the cornea — into Schlemm's canal and the episcleral veins (the conventional pathway, ~80–90%). A smaller fraction leaves through the uveoscleral pathway.

Intraocular pressure (IOP) is the equilibrium between inflow and outflow, captured by the Goldmann equation IOP = (F ÷ C) + P_v, where F is aqueous production, C is outflow facility, and P_v is episcleral venous pressure. Normal IOP runs 10–21 mmHg (mean ≈ 15–16), with a diurnal swing of a few mmHg. The whole point of this section: pressure is a drainage problem far more often than a production one — and in open-angle glaucoma, the drain clogs while the angle stays anatomically wide open.

What goes wrong: the causal chain to a dying optic nerve

In primary open-angle glaucoma the drainage angle looks open on examination, yet outflow facility (C) falls. The obstruction is microscopic and lives within the trabecular meshwork and juxtacanalicular tissue.

1. Meshwork resistance rises. Trabecular cells drop out with age, extracellular matrix accumulates, and the juxtacanalicular tissue stiffens — increasing resistance to aqueous egress.
2. IOP climbs (or the nerve proves abnormally pressure-sensitive even at 'normal' IOP — see normal-tension glaucoma).
3. The optic nerve head bears the load. Retinal ganglion cell axons pass through the lamina cribrosa, a perforated collagen plate at the back of the eye. Elevated IOP mechanically deforms and posteriorly bows the lamina, compressing the axons in its pores.
4. Axonal transport fails. This blockade starves ganglion cells of retrograde neurotrophic support (e.g., BDNF) from the brain, triggering apoptosis. Compromised perfusion of the optic nerve head adds an ischemic hit.
5. Ganglion cells die and the cup enlarges. As axons are lost, the central 'cup' of the optic disc widens — the hallmark cupping — and a matching arcuate defect appears in the visual field.

Critically, the loss follows the anatomy of the nerve fiber layer: fibers entering the superior and inferior poles of the disc are hit first, producing arcuate (Bjerrum) scotomas and nasal steps in the mid-periphery — not central blur. That is why sight is stolen from the edges inward.

Why it is silent — and what patients finally notice

Three features conspire to keep the disease invisible. First, it is painless: pressures in the 20s and low 30s stretch tissue slowly and do not trigger the acute corneal edema and trigeminal pain of angle closure. Second, it is peripheral-first, sparing the fixation-dense macula until late. Third, and most deceptively, the brain fills in the missing field using the other eye and prior expectations, so paracentral islands and arcuate gaps go unperceived.

By the time a patient reports symptoms, damage is usually advanced. Complaints include missing steps or curbs, bumping into door frames on one side, difficulty driving, and — late — a shrinking 'tunnel' of vision. Central acuity (the 20/20 line) can remain normal until the very end, which is exactly why an acuity chart alone cannot rule out glaucoma. Estimates suggest that by the time a dense field defect is symptomatic, on the order of 25–40% of retinal ganglion cells may already be gone. Because axons do not regenerate, this loss is permanent.

How it is diagnosed: the glaucoma triad of tests

Diagnosis rests on three pillars, and no single one suffices:

• Tonometry (IOP). Goldmann applanation is the reference standard. Values persistently > 21 mmHg raise suspicion, but IOP must be interpreted against central corneal thickness (CCT) — a thin cornea (< 555 µm) causes tonometry to underestimate true pressure and independently raises risk. Roughly 30–50% of POAG patients have IOP in the 'normal' range at diagnosis (normal-tension glaucoma).
• Optic disc & nerve fiber layer. On exam, look for an enlarged cup-to-disc ratio (> 0.6, or asymmetry > 0.2 between eyes), focal notching of the neuroretinal rim, and disc hemorrhages. OCT quantifies retinal nerve fiber layer and ganglion cell thinning, often before fields change.
• Perimetry (visual fields). Standard automated perimetry (e.g., Humphrey 24-2) reveals arcuate scotomas, nasal steps, and generalized depression, and — crucially — tracks progression over time.

Gonioscopy confirms the angle is open, distinguishing POAG from angle-closure. The diagnosis is fundamentally about structure-function correlation: characteristic optic-nerve damage matched by a corresponding field defect, with an open angle.

Risk factors, epidemiology, and the untreated natural history

Glaucoma affects an estimated > 70 million people worldwide and is the leading cause of irreversible blindness. Prevalence rises sharply with age — from ~1% in the 40s to ~3–8% by the 70s–80s. Key risk factors: elevated IOP (the only modifiable one), older age, African or Afro-Caribbean ancestry (higher prevalence, earlier and more aggressive), family history (first-degree relative roughly doubles–triples risk), high myopia, thin central cornea, and larger cup-to-disc ratio at baseline. The Ocular Hypertension Treatment Study quantified this: among patients with IOP 24–32 mmHg but no damage ('ocular hypertension'), about 9.5% untreated progressed to glaucoma over 5 years, roughly halved to 4.4% with treatment.

Untreated natural history: field loss creeps inexorably inward over years, arcuate defects coalesce, and the field constricts to a central and temporal island — 'tunnel vision.' The temporal crescent and central few degrees are last to go; end-stage disease can leave a fixation island of < 5° that finally fails, ending in total, permanent blindness. Progression is often silent throughout.

Treatment: lowering the one number that matters

The single evidence-based lever is reducing IOP — even in normal-tension disease, lowering pressure slows progression (the Collaborative Normal-Tension Glaucoma Study showed ~30% IOP reduction reduced progression). Treatment does not restore lost vision; it preserves what remains. Clinicians set an individualized target IOP, often a 20–30% reduction from baseline.

• Prostaglandin analogs (latanoprost, bimatoprost) — first-line drops; increase uveoscleral outflow, lower IOP ~25–33%, once nightly.
• β-blockers (timolol) — reduce aqueous production; avoid in asthma/bradycardia.
• α₂-agonists (brimonidine) and carbonic anhydrase inhibitors (dorzolamide) — reduce production; CAIs and Rho-kinase inhibitors (netarsudil, which lowers meshwork resistance) round out drops.
• Laser trabeculoplasty (SLT) — increasingly used first-line; improves trabecular outflow.
• Surgery — trabeculectomy or drainage devices when medical/laser therapy fails; creates a new outflow pathway.

Worked example: a 64-year-old African-Caribbean man has no symptoms but 20/20 vision; screening shows IOP 26 mmHg both eyes, CCT 510 µm (thin → true pressure higher still), cup-to-disc 0.75 with inferior notching, and a superior arcuate field defect. Diagnosis: POAG. He starts nightly latanoprost, IOP falls to 17 mmHg, and serial OCT/fields are monitored for stability — the goal being to keep his remaining axons alive for the rest of his life.

Open-angle vs. acute angle-closure glaucoma — two very different diseases that share a name

Feature	Primary open-angle glaucoma	Acute angle-closure glaucoma
Onset	Chronic, over years	Sudden, over hours
Drainage angle	Open on gonioscopy	Anatomically closed/occludable
Symptoms	None until advanced	Severe eye pain, headache, nausea, halos
Typical IOP	Mildly ↑ (often 22–35 mmHg) or normal	Very high, often 40–70+ mmHg
Urgency	Routine chronic management	Ophthalmic emergency — treat within hours